At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 400 enrolled
Drug / intervention
LY2495655 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Randomized Study to Investigate the Efficacy and Safety of LY2495655 Versus Placebo in Older Patients Undergoing Elective Total Hip Arthroplasty
In Brief
A Phase 2 clinical trial evaluating LY2495655 and Placebo for Muscular Atrophy. Completed, enrolled 400 participants across 45 sites in 11 countries.
Detailed Summary
The primary objective of this study is to test the hypothesis that appendicular lean body mass (aLBM) will increase after 12 weeks of LY2495655 treatment versus placebo in older participants undergoing elective total hip arthroplasty (eTHA).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMuscular Atrophy
CountriesAustria, Belgium, Canada, Denmark, Estonia, Finland, France, Japan, Spain, Sweden, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJun 2011
Enrollment StartJul 2011
Primary CompletionFeb 2014
TodayJul 2026
First PostedJun 9, 2011
Enrollment StartJul 1, 2011
Primary CompletionFeb 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 15.1 years ago
Interventions
LY2495655drug
Administered subcutaneously
Placebodrug
Administered subcutaneously